Dosing Variability and Clinical Outcomes of Oxybutynin: A Pediatric Cohort of Patients With Neurogenic Bladder

Neurogenic bladder is a common issue for children with spinal cord problems, leading to potential kidney damage if not treated early. Oxybutynin is a common medication used to manage this condition. This study looked at how oxybutynin is used in children with neurogenic bladder, focusing on the dose given, other medications they take, and bladder function tests. The study found that there's a wide range in the amount of oxybutynin prescribed and that some children still had high bladder pressures even on the highest recommended dose, which suggests the need to understand why some children respond differently to the medication.

• 1
  There was significant variability in oxybutynin dosing among the pediatric patients with neurogenic bladder, with the median daily dose being 0.36 mg/kg.
• 2
  A considerable proportion of patients (38%) with a detrusor leak point pressure (DLPP) greater than 40 cm H2O were on or exceeding the maximum guideline-recommended dose of oxybutynin.
• 3
  The wide dosing variability and high DLPPs despite maximal dosing indicate a need for further investigation of oxybutynin’s bioavailability in this population compared to its side effects and clinical outcomes.